The clinical impact of the Covid-19 pandemic first wave on patients with cystic fibrosis in New York

Simonson, Joseph; Esposito, Christine Tanaka; Frantzen, T.; Espinal, Aileen; Romano, Serena; Ramdeo, Ramona; Trentacoste, Jessica; Tsang, Donna; Vecchia, Geralyn La; Abdullah, Robert; Berdella, Maria; Bonitz, Lynn; Condos, Rany; Constantinescu, Andreï; DeCelie-Germana, Joan; DiMango, Emily; Draine, Myah; Gimeli, Tara; Giusti, Robert; Guzman, Jessenia; Hammouda, Soumia; Keating, Claire; Kier, Catherine; Lennox, Alison; Liriano, Carmen; Messer, Zachary R.; Plachta, Amy; Sadeghi, H; Schwind, Elinor Langfelder; Stables-Carney, Teresa; Walker, Patricia; Wang, Janice

doi:10.1016/j.jcf.2022.02.012

Cited by 10 publications

(35 citation statements)

References 28 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, 14.4% were diagnosed with post-traumatic stress disorder [ 37 ]. Statistically significantly increased incidences of anxiety amongst CF patients during the pandemic was also shown in a study by Simonson et al [ 34 ].…”

Section: Discussionsupporting

confidence: 60%

“…A slight increase was reported by the small sample study by Rhoads et al, from 8.9% of respondents showing depression symptoms in 2019 to 10% in 2020 [ 33 ]. A New-York-based study also presented elevated levels of depression in CF patients during the COVID-19 pandemic, from 38% to 45%, but the results were statistically insignificant [ 34 ]. In our study, the amount of mild depression symptoms was in both groups, with 15.38% before and 14.29% during the pandemic, but moderate symptoms were only present in the before group (7.69%).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Mental Health of Cystic Fibrosis Patients and the COVID-19 Pandemic in Poland: A Single-Center Comparative Study

Humaj-Grysztar

Rachel

Śmiech-Michalec

et al. 2022

IJERPH

View full text Add to dashboard Cite

Research shows that people with cystic fibrosis are more prone to suffer from psychological problems than healthy people; thus, the outbreak of the COVID-19 pandemic in Poland could have had an impact on their mental health. To assess this impact, we examined the mental health of patients before and during the pandemic. Survey participants were asked to fill in questionnaires that consisted of Beck Depression Inventory (BDI), 12-Item General Health Questionnaire (GHQ-12) and Cystic Fibrosis Questionnaire-Revised (CFQ-R; for the purpose of the study, an emotional functioning domain was used) during their hospital visits. A total of 81 patients took part in the study: 39 before the COVID-19 pandemic (BP) and 42 during the COVID-19 pandemic (DP). Patients’ medians were lower for the BDI, GHQ-12 and higher for the emotional domain of CFQ-R during the pandemic (3, 6, 75 vs. 4, 10, 73.33). Fewer patients felt that their mental health had deteriorated during the pandemic (Δχ2 = 7.723; p = 0.005), and GHQ-12 scores were lower in the DP group (Z = −3.044; p = 0.002). No significant differences were found between groups in terms of experiencing depressive symptoms (Δχ2 = 1.036; p = 0.309). It was found that patients with cystic fibrosis from our study group not only maintained but also improved their mental health state during the COVID-19 pandemic.

show abstract

Section: Discussionsupporting

confidence: 60%

Section: Discussionmentioning

confidence: 99%

Mental Health of Cystic Fibrosis Patients and the COVID-19 Pandemic in Poland: A Single-Center Comparative Study

Humaj-Grysztar

Rachel

Śmiech-Michalec

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…In France, 15% were considered severely infected due to the need for intensive care unit level care, respiratory support, or death 51 . In New York, 8% of those infected required hospitalization 52 . Overall, these studies revealed consistent patterns of increased risk factors for admission including lower (≤40%) FEV1pp, postlung transplant, 50,51 CFRD, 50–52 and older age 50,51 .…”

Section: Infectionmentioning

confidence: 95%

“…50,51 Finally, there was an observed racial difference, with more PwCF of non-White race requiring admission. 50 Interestingly, it appears that highly effective modulator therapy could have a protective effect from severe infection 50,52 and decreased odds of admission or need for oxygen supplementation when diagnosed with COVID later in the pandemic. 50 Aside from infection rates, the COVID-19 pandemic also had an impact on patient care with a rapid transition to telehealth and reduction of in-person visits.…”

Section: Additional Reportsmentioning

confidence: 99%

Cystic fibrosis year in review 2022

Kim,

Lyman,

Savant

2023

Pediatric Pulmonology

View full text Add to dashboard Cite

Remarkable medical advancements have been made for people with cystic fibrosis (CF) in recent years, with an abundance of research continuing to be conducted worldwide. With concern for limitations in access to highly effective CFTR modulators, as well as the recent Coronavirus Disease‐19 pandemic, there has been a consistent effort to understand and improve CF screening, disease burden, diagnosis, and management. Our aim in this review is to present articles from 2022 with an emphasis on clinically relevant studies. We hope this will serve as a broad overview of the research published in the past year.

show abstract

“…Additionally, some patients discontinue CFTR therapy or prefer on/off treatment with CFTR modulators rather than continuous therapy [ 70 ]. Furthermore, the global pandemic adds the risk of patients not being treated or patients not adhering to therapy in the new-normal scenario [ 71 ].…”

Section: Role Of Antibiotics Amid Cftr Modulatorsmentioning

confidence: 99%

Role of inhaled antibiotics in the era of highly effective CFTR modulators

et al. 2023

View full text Add to dashboard Cite

Recurrent and chronic bacterial infections are common in people with cystic fibrosis (CF) and contribute to lung function decline. Antibiotics are the mainstay in the treatment of exacerbations and chronic bacterial infection in CF. Inhaled antibiotics are effective in treating chronic respiratory bacterial infections and eradicatingPseudomonas aeruginosafrom the respiratory tract, with limited systemic adverse effects. In the past decade, highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators have become a new therapy that partially corrects/opens chloride transport in patients with selected CFTR mutations, restoring mucus hydration and improving mucociliary clearance. The recent triple CFTR modulator combination is approved for ∼80–90% of the CF population and significantly reduces pulmonary exacerbations and improves respiratory symptoms and lung function. CFTR modulators have shifted the focus from symptomatic treatment to personalised/precision medicine by targeting genotype-specific CFTR defects. While these are highly effective, they do not fully normalise lung physiology, stop inflammation or resolve chronic lung damage, such as bronchiectasis. The impact of these new drugs on lung health is likely to change the future management of chronic pulmonary infections in people with CF. This article reviews the role of inhaled antibiotics in the era of CFTR modulators.

show abstract

The clinical impact of the Covid-19 pandemic first wave on patients with cystic fibrosis in New York

Cited by 10 publications

References 28 publications

Mental Health of Cystic Fibrosis Patients and the COVID-19 Pandemic in Poland: A Single-Center Comparative Study

Mental Health of Cystic Fibrosis Patients and the COVID-19 Pandemic in Poland: A Single-Center Comparative Study

Cystic fibrosis year in review 2022

Role of inhaled antibiotics in the era of highly effective CFTR modulators

Contact Info

Product

Resources

About